Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hangzhou Innogate Pharma
Hangzhou, Zhejiang, Chinainnogatepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Innogate Pharma is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses primarily on two major therapeutic areas: metabolic diseases, particularly Type 2 diabetes, and oncology, with a focus on hormone-driven cancers like breast and prostate cancer. Their lead program, IG-101, is a novel glucokinase activator designed to improve glucose homeostasis in diabetic patients. Innogate leverages its expertise in medicinal chemistry to develop next-generation degraders and modulators, aiming to address unmet medical needs in the global healthcare market.
- Therapeutic areas
- EndocrinologyMetabolic DisordersOncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Hangzhou Innogate Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Innogate Pharma.